c
c 


 
  
 c 

u Biocon is India's leading
biotechnology enterprise.

u Biocon is India's first

biotechnology company
established in November 29,
1978.

u It·s headquarters is in Bangalore

,India.
u It·s CEO and MD is Kiran
Mazumdar Shaw.

u The company serves partners

and customers in over 50
countries. Within the
biotechnology space, the
company ranks 1st in Asia in
terms of revenues and market
capitalization and 16th globally.
u Biocon is the country's first
biotechnology company to
export microbial enzymes to
USA and Europe.

u Biocon is the first

biotechnology company to
receive ISO 9001 certification
in India.
u Biocon is the first company to
manufacture insulin using a
Pichia expression system

u Biocon became the first Indian

biotech company to receive US
funding for proprietary
technologies. In 1993, Biocon's R&D
and manufacturing facilities
received ISO 9001 certification.
u Yaunched India's 1st cancer
drug BYOMAb EGFR.

u India·s largest producer and

exporter of enzymes.

nd
u 2 Indian company to cross
the US $ 1 bn mark on the day
of listing.
 à




u Biopharmaceuticals
u Enzymes
u Custom research
u Clinical research
 c
c 

 
   c 
u Biocon's success has been
characterized by an enduring set of
corporate values based on :-
:-
Innovation
Integrity
Strong leadership
Social responsibility
u The company mission is to
'Develop novel & affordable
Biotherapeutics for global markets'.
u ´Earn as you learn.µ For 25 years
this unofficial philosophy had
served Biocon well.
u Starting out in the enzyme
business in 1978, the Bangalore-
Bangalore-
based firm had gradually
expanded into the pharmaceutical
industry.
u It·s recently developed capabilities
and the political, biological,
intellectual, and financial benefits of
the Indian environment to move
into new areas of opportunity.
u The company applies its proprietary
fermentation technologies to make
effective and innovative biomolecules
in diabetology, oncology, cardiology
and other therapeutic segments.
u With its strong focus on R&D

u In custom research (Syngene) in the

fields of synthetic chemistry and
molecular biology in early stage
drug discovery and development.

u Clinical research (Clinigene) is carried

out in the fields of clinical studies
and clinical trials.
u The Innovation Matrix: A Strategic
Framework

u To navigate the challenges of

innovation in the next decade we
have adopted a well-
well-defined
strategic framework that will
transform scientific discoveries
into advances in human healthcare
and generate incremental value
for our shareholders.
u Biocon's integrated business
approach has enabled the company
to establish a significant presence in
the global biopharmaceutical market
via its product offerings and
customized, high value solutions at
any stage in the lifecycle of a drug
from discovery to market.

u Biocon·s vision is to be an integrated

biopharmaceutical enterprise of
global distinction.
u †Our ability to continuously scale
new heights across the
biopharmaceutical value chain
enables us to realize the promise of
future therapeutics.† -Kiran
Mazumdar--Shaw, Chairman &
Mazumdar
Managing Director.

u Biocon is thus rapidly moving

towards commercializing novel
biologics with a †Made in India† label.
u As India's first and leading
biotechnology company Biocon
extends its support to numerous
community outreach and corporate
citizenship initiatives with special
concentration in the areas of
healthcare, education and
environment.

u The Biocon Foundation, set up in

2004 has launched Arogya Raksha
Yojana, a unique health initiative for
rural India.